Recent advances in the understanding and management of liposarcoma.

Liposarcomas are a common subfamily of soft tissue sarcoma with several subtypes recognized by the World Health Organization: atypical lipomatous tumors (ALT)/well-differentiated liposarcoma (WDLPS), dedifferentiated liposarcoma (DDLPS), myxoid liposarcoma (MLPS), pleomorphic liposarcoma (PLPS), and myxoid pleomorphic liposarcoma (MPLPS). Despite shared adipocytic features among liposarcomas, the clinical approach to each subtype differs based on histology, location, clinical behavior, and specific oncogenic drivers. In this review, we highlight subtype-specific molecular features with the potential to generate novel therapies. We discuss recent clinical trials investigating the use of preoperative radiation therapy for retroperitoneal liposarcoma, chemotherapy, small molecule inhibitors, and innovative immunotherapy approaches and describe how we incorporate these advancements into the management of liposarcoma.
Competing Interests: Richard F. Riedel has received institutional clinical research support from Aadi, AROG, Blueprint, Daiichi Sankyo, Deciphera, GlaxoSmithKline, Karyopharm, Ignyta, Immune Design, Lilly, NanoCarrier, Novartis, Oncternal, Plexxikon, Roche, Springworks, Threshold, and TRACON. He has served as a consultant or advisor for Bayer, Blueprint, Daiichi Sankyo, Deciphera, Eisai, EMD Serono, Janssen, Lilly, Loxo, NanoCarrier, and Springworks. Candace L. Haddox declares that she has no competing interests.No competing interests were disclosed.No competing interests were disclosed.
(Copyright: © 2020 Haddox CL et al.)